JP2019145162A - サプリメント創造探索システム - Google Patents
サプリメント創造探索システム Download PDFInfo
- Publication number
- JP2019145162A JP2019145162A JP2019084721A JP2019084721A JP2019145162A JP 2019145162 A JP2019145162 A JP 2019145162A JP 2019084721 A JP2019084721 A JP 2019084721A JP 2019084721 A JP2019084721 A JP 2019084721A JP 2019145162 A JP2019145162 A JP 2019145162A
- Authority
- JP
- Japan
- Prior art keywords
- association
- supplement
- component
- components
- degree
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013589 supplement Substances 0.000 title claims abstract description 182
- 238000011156 evaluation Methods 0.000 claims description 52
- 238000013473 artificial intelligence Methods 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 6
- 238000013075 data extraction Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 description 39
- 238000004891 communication Methods 0.000 description 34
- 208000008589 Obesity Diseases 0.000 description 23
- 235000020824 obesity Nutrition 0.000 description 23
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 20
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 20
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 20
- 235000005487 catechin Nutrition 0.000 description 20
- 229950001002 cianidanol Drugs 0.000 description 20
- 230000008030 elimination Effects 0.000 description 20
- 238000003379 elimination reaction Methods 0.000 description 20
- 229930003451 Vitamin B1 Natural products 0.000 description 19
- 229960003495 thiamine Drugs 0.000 description 19
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 19
- 235000010374 vitamin B1 Nutrition 0.000 description 19
- 239000011691 vitamin B1 Substances 0.000 description 19
- 240000002234 Allium sativum Species 0.000 description 17
- 108091000080 Phosphotransferase Proteins 0.000 description 17
- 235000004611 garlic Nutrition 0.000 description 17
- 239000008187 granular material Substances 0.000 description 17
- 102000020233 phosphotransferase Human genes 0.000 description 17
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 10
- 235000019161 pantothenic acid Nutrition 0.000 description 10
- 229940055726 pantothenic acid Drugs 0.000 description 10
- 239000011713 pantothenic acid Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000037393 skin firmness Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 6
- 235000013734 beta-carotene Nutrition 0.000 description 6
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 6
- 239000011648 beta-carotene Substances 0.000 description 6
- 229960002747 betacarotene Drugs 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000001276 controlling effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000019152 folic acid Nutrition 0.000 description 5
- 229960000304 folic acid Drugs 0.000 description 5
- 239000011724 folic acid Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000003631 expected effect Effects 0.000 description 4
- 238000005065 mining Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 102000010445 Lactoferrin Human genes 0.000 description 3
- 108010063045 Lactoferrin Proteins 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 3
- 229940078795 lactoferrin Drugs 0.000 description 3
- 235000021242 lactoferrin Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013135 deep learning Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P90/00—Enabling technologies with a potential contribution to greenhouse gas [GHG] emissions mitigation
- Y02P90/30—Computing systems specially adapted for manufacturing
Landscapes
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
Description
本発明を適用したサプリメント創造探索システム1は、例えば図1に示すような構成により具現化される。このサプリメント創造探索システム1は、システムを利用するユーザ用の端末11と、この端末11に対して公衆通信網12を介して接続されるサーバ13とを備えている。
次に本発明を適用したサプリメント創造探索システム1の本実施形態について説明をする。この本実施形態では、上述した参考実施形態において説明したサプリメント創造探索システム1を使用して、新たに創造すべきサプリメントの成分探索を行う。このため、このサプリメント創造探索システム1の構成の説明は、参考実施形態における説明を引用することにより、以下での説明を省略する。
4 公衆通信網
11 端末
12 公衆通信網
13 サーバ
21 内部バス
24 制御部
25 操作部
26 表示部
27 記憶部
29 データ入出力部
31 音声入力部
Claims (7)
- 2以上の既存のサプリメントを構成する各成分間の連関度が規定された第5連関性を予め記憶したデータベースと、
新たに創造すべきサプリメントの条件として、含有させたい成分が規定された期待成分情報を取得する期待成分情報取得手段と、
上記データベースにおいて記憶された第5連関性を参照し、上記期待成分情報に規定された各成分に応じた他の成分の組み合わせを探索する探索手段とを備えること
を特徴とするサプリメント創造探索システム。 - 上記データベースは、上記連関度の重み付けがその成分間の配合比率、又はその成分の組み合わせの出現頻度に基づいて予め決定された第5連関性を記憶すること
を特徴とする請求項1記載のサプリメント創造探索システム。 - 上記探索手段は、上記期待成分情報取得手段により取得された各成分と他の成分との連関度、並びに他の成分同士の連関度に基づいて、新たに創造すべきサプリメントの成分組成を選択すること
を特徴とする請求項1又は2記載のサプリメント創造探索システム。 - 上記探索手段は、各成分と他の成分との連関度、並びに他の成分同士の連関度の総合計値、各連関度の平均値、各連関度の分散の何れか1以上に基づいて新たに創造すべきサプリメントの成分組成を選択すること
を特徴とする請求項1〜3のうち何れか1項記載のサプリメント創造探索システム。 - 上記探索手段は、上記第5連関性における成分の含有比率に基づいて上記他の成分の組み合わせを探索すること
を特徴とする請求項1〜4のうち何れか1項記載のサプリメント創造探索システム。 - 上記探索手段は、人工知能により制御されること
を特徴とする請求項1〜5のうち何れか1項記載のサプリメント創造探索システム。 - 上記探索されたサプリメントの評価結果が反映された評価データを抽出する評価データ抽出手段を更に備え、
上記探索手段を制御する人工知能は、上記評価データ抽出手段により抽出された評価データを上記各連関性に反映させること
を特徴とする請求項6項記載のサプリメント創造探索システム。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019084721A JP6845513B2 (ja) | 2019-04-25 | 2019-04-25 | サプリメント創造探索システム |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019084721A JP6845513B2 (ja) | 2019-04-25 | 2019-04-25 | サプリメント創造探索システム |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016081909A Division JP6635417B2 (ja) | 2016-04-15 | 2016-04-15 | サプリメント創造探索システム |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019145162A true JP2019145162A (ja) | 2019-08-29 |
JP6845513B2 JP6845513B2 (ja) | 2021-03-17 |
Family
ID=67772544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019084721A Active JP6845513B2 (ja) | 2019-04-25 | 2019-04-25 | サプリメント創造探索システム |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6845513B2 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003223515A (ja) * | 2001-11-22 | 2003-08-08 | Pharma Design Inc | 各個人に適した栄養補助食品または疾患予防食品の提供システムおよび当該食品の製造方法 |
JP2011232989A (ja) * | 2010-04-28 | 2011-11-17 | Hirotaro Matsui | サプリメント提案方法、及びそのシステム、プログラム、記憶媒体 |
-
2019
- 2019-04-25 JP JP2019084721A patent/JP6845513B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003223515A (ja) * | 2001-11-22 | 2003-08-08 | Pharma Design Inc | 各個人に適した栄養補助食品または疾患予防食品の提供システムおよび当該食品の製造方法 |
JP2011232989A (ja) * | 2010-04-28 | 2011-11-17 | Hirotaro Matsui | サプリメント提案方法、及びそのシステム、プログラム、記憶媒体 |
Also Published As
Publication number | Publication date |
---|---|
JP6845513B2 (ja) | 2021-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109964280B (zh) | 用于计算、显示、修改和使用改善的个性化营养健康评分来评估和计划最佳饮食的系统和方法 | |
Marí-Bauset et al. | Comparison of nutritional status between children with autism spectrum disorder and typically developing children in the Mediterranean Region (Valencia, Spain) | |
Antin et al. | Food choice as a multidimensional experience. A qualitative study with young African American women | |
Klos et al. | Marital status and body weight, weight perception, and weight management among US adults | |
JP6112591B1 (ja) | 創作物供給システム | |
JP6705089B2 (ja) | ヘルスチューニング支援システム | |
Kokkoris et al. | Meaning of food and consumer eating behaviors | |
JP7239220B2 (ja) | 栄養摂取量の推定装置、健康管理支援装置、栄養摂取量の推定方法、健康管理支援方法、プログラムおよび栄養摂取量の推定システム | |
US20220406215A1 (en) | Systems and methods for dynamically providing dynamic nutritional guidance | |
Malik et al. | The revised nutrition facts label: a step forward and more room for improvement | |
Sosa et al. | Associations between a voluntary restaurant menu designation initiative and patron purchasing behavior | |
Sharp et al. | Validity and reliability of the Food-Life Questionnaire. Short form | |
JP2020506477A (ja) | 個人遺伝子のプロフィールに基づいて購入勧告を決定して、提示するためのシステム及び方法 | |
Woolley | Aberrant consumers: Selfies and fat admiration websites | |
JP2019113949A (ja) | 処方探索システム及び方法、処方探索プログラム | |
JP6635417B2 (ja) | サプリメント創造探索システム | |
US20230207102A1 (en) | Genetically personalized food recommendation systems and methods | |
KR20210052123A (ko) | 사용자 맞춤형 식품 정보 서비스를 제공하는 방법 및 그를 이용한 서버 | |
JP6845513B2 (ja) | サプリメント創造探索システム | |
JP7473247B2 (ja) | 食事提案支援装置、食事提案支援方法、食事提案支援端末、食事提案支援システム、プログラム、および記録媒体 | |
Wisniewski | The weight of communication: The Canadian Medical Association Journal’s discourse on obesity | |
Giannattasio et al. | Crafting a healthier future: exploring the nexus of product design, digital innovations and dynamic marketing for obesity prevention. A literature review | |
Fortin et al. | Typology of Canadian alcohol users: relationships between use, context, and motivation to drink in the definition of drinking profiles | |
US20230099235A1 (en) | Nutrition tracking system that utilizes nutrition information on packaged food label and generates graph indicative of health rating | |
Tezçi et al. | Unlocking the potential of nutrition labels: A look at the power of (digital) nudges |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190731 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200828 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6845513 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |